Eren, S., Tonin, G., Jurii Eren, D., & Klen, J
Body Composition and Metabolic Parameters Research on component peptides revealed favorable effects on body composition and metabolic markers[10]: Significant reductions in waist circumference (10-15 cm reductions observed) Preferential visceral fat loss documented through imaging studies Preserved lean body mass relative to total weight loss in most studies Improved body composition ratios with fat mass reductions exceeding total weight loss percentages Type 2 Diabetes Research Glycemic Control Studies Investigations in type 2 diabetes models demonstrated robust glucose-lowering effects[11]: HbA1c reductions of 2.0-2.4% observed with GLP3 in phase 2 diabetes trials Fasting plasma glucose reductions of 40-60 mg/dL documented across dose ranges Improved continuous glucose monitoring parameters including time in range and glucose variability CagriSema combination achieved superior glycemic control compared to individual components Studies showed that 72% of participants with prediabetes reverted to normoglycemia with GLP3 treatment, suggesting potential diabetes prevention applications[12]
GLP-1 receptor agonists like semaglutide and GHRH analogues such as tesamorelin have received the FDA's stamp of approval with evidence from studies backing them up
(The new advisory panel includes several members with ties to the peptides industry, raising concerns about its impartiality.) After the first day of deliberation, the panel voted in favor of easing restrictions on two popular peptidesBPC-157 and KPVdespite the fact that other FDA scientists have publicly raised concerns about the lack of evidence for these compounds
Compounded medications have not been approved by the FDA for safety, effectiveness, or quality and should only be used when FDA-approved medications are unavailable
